EXTH-13. REDUCTION OF TUMOR BURDEN AND HEARING LOSS WITH A MULTIPLE RECEPTOR TYROSINE KINASE INHIBITOR BRIGATINIB IN A GENETICALLY ENGINEERED MOUSE MODEL OF NEUROFIBROMATOSIS TYPE 2 | Zendy

AI Assistant Blog Pricing

EXTH-13. REDUCTION OF TUMOR BURDEN AND HEARING LOSS WITH A MULTIPLE RECEPTOR TYROSINE KINASE INHIBITOR BRIGATINIB IN A GENETICALLY ENGINEERED MOUSE MODEL OF NEUROFIBROMATOSIS TYPE 2

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.